Compare Mondaycom Ltd (MNDY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Mondaycom Ltd trades at $88.92 (market cap $3.76B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.7× Mondaycom Ltd's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MNDY | XBI | |
|---|---|---|
Market Cap | $3.76B | $10.11B |
Volume | 836,200 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $205.24 | $169.55 |
52-Week Low | $58.81 | $104.99 |
Typical Hold Time | 16 Days | 38 Days |
Enterprise Value | $2.92B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $88.41, up 5.87% in the last session, showing strong momentum near 52-week highs. The stock maintains a bullish technical outlook with consistent earnings beats and robust revenue growth. Recent Q2 2026 EPS of $1.48 exceeded expectations by 33%, while enterprise customer growth accelerated to 37% year-over-year. The company's Elevate '26 conference highlights AI integration efforts, positioning it for continued market share gains in the work management software sector.
With 65% analyst buy ratings and a $108.64 consensus price target, MNDY offers 23% upside potential. However, elevated valuation multiples (P/E 37.7, EV/EBITDA 53.5) and increasing competition from Meta's enterprise push present near-term risks. The stock's current RSI near 88 suggests overbought conditions, though fundamental growth drivers remain intact for long-term investors.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
